No significant differences were observed between IDH-wildtype and IDH-mutant gliomas (OR 0.72, 95% CI 0.26–2.02) or between intracranial and lumbar CSF collection techniques (p > 0.9). The gene discussed is IDH2; the disease is central nervous system cancer.